Access to AIDS medicines and diagnostics

Access to diagnostic tests and medicines is an essential requirement to ensure the delivery of HIV prevention, treatment and care programmes. In order to support improved availability of HIV medicines and diagnostics, WHO convenes the AIDS Medicines and Diagnostics Service (AMDS), a network of technical partners providing support and guidance to countries in procurement and supply management of HIV commodities. The WHO HIV/AIDS Department hosts the AMDS secretariat.

The main output of the AMDS is developing strategic information on HIV drugs and diagnostics, publishing an annual forecast on global demand for antiretrovirals (ARVs) and supporting capacity building activities for health supply chains.

The AMDS’ strategic information work focuses on procurement, regulatory status, and availability of the active ingredients of ARVs and on the sources and prices of methadone and buprenorphine (used in opioid substitution treatment) and drugs used for HIV opportunistic infections. Tracking procurement of HIV diagnostics, and drugs and commodities for tuberculosis and malaria has been added into AMDS portfolio recently.

AMDS tracking includes over 80% of all internationally-funded ARV procurement transactions with low- and middle-income countries, as a result of AMDS’ close collaboration with partners such as the US PEPFAR, GFATM, UNICEF, IDA Foundation, UNITAID, MissionPharma, the Global Drug Facility for TB, WHO Central Procurement Services, Clinton Foundation’s Health Access Initiative, Management Sciences for Health, and USAID/Deliver.

This partnership enables price benchmarking in the ARV procurement and assessing of market trends in low- and middle-income countries. The strategic information compiled by AMDS and its ARV demand forecasts are publicly made available on this website.